Arrhythmias - Pipeline Review, H2 2020
- $ 2000
- April 2024
- 86 pages
Additionally, the patent covers the ability of GR-MD-## to enhance the eff ectiveness of immune modulators in a variety of cancers, including gastrointestinal cancer, pancreatic cancer, bile duct cancer, sarcoma, myosarcoma, breast cancer, lung cancer, head and neck cancer, mouth cancer, skin cancer, melanoma, kidney cancer, urinary tract cancer, prostate cancer, testicular cancer, ovarian cancer, endometrial cancer, neurological cancer, endocrine gland cancer, bone cancer, hematological cancers, multiple myeloma, and myelof ibrosis.